There is an unmet need for specific, cost-effective, and easily detectable biomarkers for (elder) population screening to intercept intermediate phases of pathological evolution, from amyloid β plaques to astrocyte reactivity (Glial Fibrillary Acidic Protein—GFAP), Tau tangle formation and severe cognitive impairment. This evidence concerns the gene GFAP and Cognitive impairment.